Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer

Molecular Cancer

Volumn 8, Issue , 2009, Pages 74-

  Uddin, Shahab ^a   Bu, Rong ^a   Ahmed, Maqbool ^a   Abubaker, Jehad ^a   Al Dayel, Fouad ^a   Bavi, Prashant ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LEPTIN; LEPTIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL X; PROTEIN KINASE B; SMALL INTERFERING RNA;

ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, SERUM-FREE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LEPTIN; MIDDLE AGED; MIDDLE EAST; ONCOGENE PROTEIN V-AKT; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, LEPTIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 70449377000     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-74     Document Type: Article

References (37)

1. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001, 22:255-258. 10.1210/er.22.2.255, 11294827.
2. Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, Senn H. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005, 68:293-298. 10.1159/000086967, 16020955.
3. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998, 25:340-348.
4. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007, 4:195-208.
5. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007, 67:2497-2507. 10.1158/0008-5472.CAN-06-3075, 17363567.
6. Abu-Abid S, Szold A, Klausner J. Obesity and cancer. J Med 2002, 33:73-86.
7. Ognunwobi OO, Bealses LP. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis 2007, 22:401-409. 10.1007/s00384-006-0181-y, 16912864.
8. Choi JH, Park SH, Leung PC, Choi KC. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 2005, 90:207-210. 10.1210/jc.2004-0297, 15522945.
9. Huang L, Li C. Leptin: a multifunctional hormone. Cell Res 2000, 10:81-92. 10.1038/sj.cr.7290038, 10896170.
10. Bouloumié A, Drexler HC, Lafontan M, Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998, 83:1059-1066.
11. Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR. Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-1686. 10.1126/science.281.5383.1683, 9733517.
12. Bjørbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997, 272:32686-32695. 10.1074/jbc.272.51.32686, 9405487.
13. Tartaglia LA. The leptin receptor. J Biol Chem 1997, 272:6093-6096.
14. Leitzmann MF, Koebnick C, Danforth KN, Brinton LA, Moore SC, Hollenbeck AR, Schatzkin A, Lacey JV. Body mass index and risk of ovarian cancer. Cancer 2009, 115:812-822. 10.1002/cncr.24086, 19127552.
15. Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI, Bhatia KG. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005, 11:3102-3108. 10.1158/1078-0432.CCR-04-1857, 15837766.
16. Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S. Overexpression of the obesity hormone leptin in human colorectal cancer. J Clin Pathol 2007, 60:902-906. 10.1136/jcp.2006.041004, 17660334.
17. Hong SJ, Kwon KW, Kim SG, Ko BM, Ryu CB, Kim YS, Moon JH, Cho JY, Lee JS, Lee MS, Shim CS, Kim BS. Variation in expression of gastric leptin according to differentiation and growth pattern in gastric adenocarcinoma. Cytokine 2006, 33:66-71. 10.1016/j.cyto.2005.11.015, 16434209.
18. Koda M, Sulkowska M, Wincewicz A, Kanczuga-Koda L, Musiatowicz B, Szymanska M, Sulkowski S. Expression of leptin, leptin receptor, and hypoxia-inducible factor 1 alpha in human endometrial cancer. Ann N Y Acad Sci 2007, 1095:90-98. 10.1196/annals.1397.013, 17404022.
19. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor [OB-R] in human breast cancer. Clin Cancer Res 2004, 10:4325-4331. 10.1158/1078-0432.CCR-03-0749, 15240518.
20. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. Natl Cancer Inst 2002, 94:1704-1711.
21. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol 2006, 207:12-22. 10.1002/jcp.20472, 16110483.
22. Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D, Barrett KE. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007, 94:346-354. 10.1002/bjs.5530, 17212381.
23. Ogunwobi OO, Beales IL. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. Int J Colorectal Dis 2007, 22:401-409. 10.1007/s00384-006-0181-y, 16912864.
24. Mitchell M, Armstrong DT, Robker RL, Norman RJ. Adipokines: implications for female fertility and obesity. Reproduction 2005, 130:583-597. 10.1530/rep.1.00521, 16264089.
25. Chen C, Chang YC, Liu CL, Chang KJ, Guo IC. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat 2006, 98:121-132. 10.1007/s10549-005-9139-y, 16752079.
26. Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactiv-ation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 2006, 147:4505-4516. 10.1210/en.2006-0224, 16740977.
27. Russel P. Surface epithelial-stromal tumors of the ovary. Blaustein's Pathology of the Female Genital Tract 1995, 705-782. New York: Springer-Verlag, Kurman RJ.
28. Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O, Uddin S, Al-Kuraya KS. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol 213:190-199. 10.1002/path.2215, 17703498.
29. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS. Clinicopathological analysis of Papillary Thyroid Cancer with PIK3CA alterations in Middle Eastern Population. J Clin Endocrinol Metab 2008, 93:611-618. 10.1210/jc.2007-1717, 18000091.
30. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005, 11:5188-5194. 10.1158/1078-0432.CCR-05-0158, 16033835.
31. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10:7252-7259. 10.1158/1078-0432.CCR-04-0713, 15534099.
32. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186. 10.1182/blood-2006-04-016907, 16946303.
33. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008, 27:3539-3545. 10.1038/sj.onc.1211013, 18193083.
34. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS. Bortezomib [Velcade] induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008, 68:3379-3388. 10.1158/0008-5472.CAN-07-6109, 18451165.
35. Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS, Uddin S. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008, 7:3318-3329. 10.1158/1535-7163.MCT-08-0541, 18852135.
36. Uddin S, Hussain A, Ahmed M, Belgaumi A, Al-Dayel F, Ajarim D, Bavi P, Al-Kuraya KS. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol 2008, 216:483-494. 10.1002/path.2433, 18850583.
37. Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA 2004, 101:47-152.